Significant variation in application of active surveillance

According to an article in the journal Cancer, men with low-risk prostate cancer diagnosed and managed at high-volume hospitals are 3.6 times more likely to be managed on active surveillance than those managed at low-volume institutions. … READ MORE …

Immunotherapy for the treatment of prostate cancer

The Society for Immunotherapy of Cancer has just issued a detailed statement on the role of immunotherapy in the management of prostate cancer. The full text of this article by McNeel et al. is available on line. … READ MORE …

An unfortunately misleading statement in the AFP

Back in 2014, the American Cancer Society (ACS) issued a really rather thorough set of guidelines on the long-term management of survivors after initial treatment for prostate cancer. … READ MORE …

NCCN expands role for active surveillance in initial management of localized prostate cancer

In its most recent update to its guidelines on the management of prostate cancer, the National Comprehensive Cancer Network (NCCN) has now stated that active surveillance is a first-line option for the management of favorable, intermediate-risk prostate cancer. … READ MORE …

NCCN issues revised prostate cancer management guidelines for 2016

The National Comprehensive Cancer Consortium (NCCN) has just released its updated 2016 guidelines on the management of prostate cancer for physicians. … READ MORE …

From the past to the future … the appropriate use of active monitoring

A new article just published in the journal Cancer concludes that “active surveillance is underused” in the management of low-risk prostate cancer. However, one has to be careful about how one interpret the data in (and the conclusions of) this particular article. … READ MORE …

Selection of appropriate candidates for management with active surveillance

In this month’s issue of the Journal of Urology, Dr. Peter Carroll (of UCSF) and Dr. Mark Dall’Era (formerly of UCSF and now at UCDavis) have contributed an editorial entitled “What is the optimal way to select candidates for active surveillance of prostate cancer?” … READ MORE …